In symptomatic isolated DVT, 12 wk vs. 6 wk of rivaroxaban reduced recurrent VTE at 24 mo

Ann Intern Med. 2023 Apr;176(4):JC42. doi: 10.7326/J23-0014. Epub 2023 Apr 4.

Abstract

Ageno W, Bertu L, Bucherini E, et al; RIDTS study group. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ. 2022;379:e072623. 36520715.

Publication types

  • Comment

MeSH terms

  • Anticoagulants / therapeutic use
  • Humans
  • Pulmonary Embolism*
  • Rivaroxaban / therapeutic use
  • Venous Thromboembolism* / chemically induced
  • Venous Thromboembolism* / drug therapy
  • Venous Thrombosis* / drug therapy

Substances

  • Rivaroxaban
  • Anticoagulants